12:00 AM
 | 
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Arena, Eisai sales and marketing update

Arena and Eisai expanded a 2010 deal under which Eisai has rights to market Arena's obesity drug Belviq lorcaserin in North America and most of South...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >